Degenerative Disc Disease Clinical Trial
Official title:
An Assessment of P-15L Bone Graft in Transforaminal Lumbar Interbody Fusion With Instrumentation
Study Design: Prospective, single-blinded, multi-center, randomized, controlled, pivotal
study Study Objective: To evaluate if P-15L is not inferior in effectiveness and safety to
local autologous bone (and allograft as extender where necessary) when applied in
instrumented TLIF in subjects with Degenerative disc disease (DDD)
Study Endpoints:
Primary endpoint: Month 24 Composite Clinical Success (CCS):
- Achievement of fusion (Evidence of continuous trabecular bridging bone in the
intervertebral space)
- At least 15-point improvement in Oswestry Disability Index (ODI)
- No new or worsening, persistent neurological deficit
- No subsequent surgical intervention at the index level
Once fusion is radiographically confirmed, it will be assumed that fusion has occurred at all
subsequent time points without the need to reconfirm fusion status at later time points.
Multiplicity Controlled Secondary endpoint:
• Visit at which fusion is confirmed.
Other Secondary endpoints:
- Visual Analog Scale (VAS) pain scores, changes over time, and achievement of a 20 mm
improvement (Back, left leg, right leg);
- Physical Function and Mental Health Composite Scores (Short Form Health Survey SF-12 and
changes over time).
Cerapedics currently markets a peptide-enhanced bone graft product, i-FACTOR putty, for use
in cervical spine degenerative disk disease. i-FACTOR putty is a composite bone substitute
material consisting of the P-15 peptide adsorbed onto anorganic bone mineral and suspended in
an inert biocompatible hydrogel carrier. P-15 is a synthetic, 15-amino acid peptide that
mimics the cellbinding domain of Type I collagen and is able to signal a mechanical and
biochemical communication pathway that ultimately results in new bone formation. The P-15
peptide enhances cell migration and induces osteoblast cell proliferation and
differentiation. P-15 is specific to anchoring-dependent connective tissue mesenchymal cells,
including osteogenic cells,and therefore does not induce bone formation in the absence of
these cells. The receptor mediated anchorage of osteoblasts by P-15 initiates a number of
signal transduction pathways that lead to the synthesis of growth factors, cytokines, and
bone morphogenetic proteins.
A prospective, randomized, controlled, multi-center clinical trial in cervical spinal fusion
demonstrated the safety and efficacy of i-FACTOR putty compared to standard-of-care autograft
(clinicaltrials.gov NCT00310440.) The results demonstrated that i-FACTOR putty was
statistically non-inferior to autograft for fusion success, improvement in Neck Disability
Index (NDI) scores, neurological success and number of adverse events, at both the 1 and 2
year time point. The i-FACTOR putty was demonstrated to be statistically superior to
autograft, at both 1 year and 2-years, for "overall success" which measures the patients that
were successful in all of the test modalities.
Cerapedics is developing a new bone graft product formulation to enhance our product
portfolio, specifically a P15-based bone graft that is appropriate for lumbar spinal fusion,
called P-15L. The new formulation comprises two new materials as compared to the original
i-FACTOR putty. The first is the use of porcine-derived anorganic bone mineral (ABM) as the
anorganic bone matrix. The second modification is the use of bovine collagen as the inert
carrier for the anorganic bone granules. The introduction of collagen as the inert carrier
will allow the P-15L to be used in a TLIF surgical indication since the collagen component
provides material integrity for the putty in the implant site.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04848376 -
Post-Market Clinical Follow-up Study of A-SPINE's Products
|
||
Active, not recruiting |
NCT05114135 -
TLIF Osteo3 ZP Putty Study (Also Known as the TOP Fusion Study)
|
N/A | |
Suspended |
NCT04735185 -
Stem Cells vs. Steroids for Discogenic Back Pain
|
N/A | |
Withdrawn |
NCT03223701 -
Efficacy of Using Solum IV and BMC With GFC in TLIF
|
Phase 4 | |
Completed |
NCT04057235 -
Retrospective Review of Integrity Implants FlareHawk® for Lumbar Fusion
|
||
Not yet recruiting |
NCT06000319 -
Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion
|
||
Active, not recruiting |
NCT02969616 -
Trinity Elite in Lumbar Fusion
|
||
Completed |
NCT02558621 -
New Robotic Assistance System for Spinal Fusion Surgery
|
N/A | |
Completed |
NCT02104167 -
Retrospective/Prospective Data Collection on the LDR ROIC Interbody Fusion Device With VerteBRIDGE Plating
|
||
Terminated |
NCT00974623 -
Bone Graft Materials Observational Registry
|
N/A | |
Completed |
NCT00996073 -
Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion
|
Phase 2 | |
Completed |
NCT00965380 -
Trinity Evolution in Posterior or Transforaminal Lumbar Interbody Fusion (PLIF/TLIF)
|
||
Completed |
NCT00758719 -
Evaluate Effectiveness of the Biomet Lumbar Spinal Fusion System
|
||
Completed |
NCT00165893 -
Comparison of IDD Therapy and Non-surgical Treatment for Low Back Pain Caused by Degenerative Disc Disease
|
Phase 4 | |
Terminated |
NCT01494493 -
Pivotal Study of rhBMP-2/ACS/Allograft Bone Dowel for Anterior Lumbar Interbody Fusion in Patients With Symptomatic Degenerative Disc Disease
|
N/A | |
Recruiting |
NCT04727385 -
Intervertebral DXM Gel Injection in Adults With Painful Lumbar Degenerative Disc Disease
|
N/A | |
Completed |
NCT04849429 -
Intra-discal Injection of Platelet-rich Plasma (PRP) Enriched With Exosomes in Chronic Low Back Pain
|
Phase 1 | |
Recruiting |
NCT04469387 -
Preventive Effect of Limited Decompression on Adjacent Segment Following Posterior Lumbar Interbody Fusion
|
N/A | |
Recruiting |
NCT04056520 -
Clinical and Radiological Outcomes of Posterior Cervical Fusion With Medtronic Infinity Occipitocervical-Upper Thoracic (OCT) System
|
||
Completed |
NCT04119466 -
Stabilizing Training in Degenerative Disc Disease
|
N/A |